Stephen Chambers ^{Top-Executive}

I left the UK because the US was where scientists were building companies. So that's where I went.
I joined Vertex Pharmaceuticals (NASDAQ:VRTX) as a founding scientist, where I got to see firsthand how great science becomes FDA-approved medicine. From there I co-founded Abpro Therapeutics (NASDAQ:ABP), using synthetic biology to rethink how antibodies are discovered and developed. Along the way I figured out that I loved building companies just as much as I loved the science, maybe more.

There's a pattern to where I've chosen to be. When I arrived in the US, Boston/Cambridge were just starting to become what they are now, a genuine hub for life science entrepreneurship. I was there at the beginning of that. So when the UK started showing the same early signs, it felt like a natural next move. I led SynbiCITE and co-founded the UK's first synthetic biology accelerator, working to give the next generation of scientist-founders a real path forward. Something that hadn't existed when I left.

New York felt the same way. That same early energy, that same sense of something just starting to take shape. As General Partner at SOSV New York, I'm investing in early-stage deep tech founders at the moment when everything is still possible and nothing is guaranteed. It's my favorite stage: raw science, big ambition, everything to prove.

If you're a scientist thinking about starting a company, or a founder navigating that awkward early stage where the idea is solid but the path isn't clear yet, I've lived that journey and I'm genuinely happy to talk.